FRAZIER LIFE SCIENCES XI, L.P. purchased 10.6% of their position (588.24K shares) of ATTOVIA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $10.00M — a moderate purchase. The strongest form of insider conviction signal.
Common Stock
Shares
+1.75M
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+1.59M
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+1.19M
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+961.32K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+588.24K
Price / share
$17.00
Trade value
$10M
% of position
Net shares
+6.08M
Net value
$10M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/6/2026 | C · Conversion | +1.75M | — | — | 2321.5% | 75.35K | 1.82M |
| Common Stock Direct | 8/6/2026 | C · Conversion | +1.59M | — | — | 87.2% | 1.82M | 3.41M |
| Common Stock Direct | 8/6/2026 | C · Conversion | +1.19M | — | — | 34.8% | 3.41M | 4.60M |
| Common Stock Direct | 8/6/2026 | C · Conversion | +961.32K | — | — | 20.9% | 4.60M | 5.57M |
| Common Stock Direct | 8/6/2026 | P · Purchase | +588.24K | $17.00 | $10M | 10.6% | 5.57M | 6.15M |
| Total | +6.08M | $10M | ||||||
Series A-1 Preferred Stock
Common Stock
1.75M shares
Shares
−16.25M
Strike price
Held after
0.00
Exercisable
—
Series A-2 Preferred Stock
Common Stock
1.59M shares
Shares
−14.77M
Strike price
Held after
0.00
Exercisable
—
Series B Preferred Stock
Common Stock
1.19M shares
Shares
−11.05M
Strike price
Held after
0.00
Exercisable
—
Series C Preferred Stock
Common Stock
961.32K shares
Shares
−8.93M
Strike price
Held after
0.00
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A-1 Preferred Stock Direct | Common Stock1.75M shares | 8/6/2026 | C · Conversion | −16.25M | — | 0.00 | |
| Series A-2 Preferred Stock Direct | Common Stock1.59M shares | 8/6/2026 | C · Conversion | −14.77M | — | 0.00 | |
| Series B Preferred Stock Direct | Common Stock1.19M shares | 8/6/2026 | C · Conversion | −11.05M | — | 0.00 | |
| Series C Preferred Stock Direct | Common Stock961.32K shares | 8/6/2026 | C · Conversion | −8.93M | — | 0.00 |